Paclitaxel and concurrent radiation for locally advanced pancreatic and gastric cancer: a phase I study.

Safran, Howard; King, Ta; Choy, Hak; Hesketh, Paul J.; Wolf, Brian; Altenhein, E.; Sikov, William M.; Rosmarin, Alan G.; Akerley, Wallace; Radie-Keane, K.; Cicchetti, Giuseppe; Lopez, Francisco F.; Ki, Bland; Wanebo, H. J.

doi:10.1200/jco.1997.15.3.901

Cited by 79 publications

(32 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Die Lokalrezidivrate mit der alleinigen Strahlentherapie, auch mit Dosen über 50 Gy, beträgt bis zu 70% [4,26]. Das Ziel der Therapie ist sowohl eine Überlebensverlängerung [26].…”

Section: Therapiekonzepte Bei Lokoregionär Begrenztem Inoperablen Panunclassified

“…Das Ziel der Therapie ist sowohl eine Überlebensverlängerung [26]. Diese Daten sind vergleichbar den Ergebnissen bei anderen Kollektiven, die Gesamtbehandlungszeit der Patienten ist jedoch um zwei bis drei Wochen kürzer [17,24,26].…”

Section: Therapiekonzepte Bei Lokoregionär Begrenztem Inoperablen Panunclassified

“…Aufgrund der schlechten Prognose werden neue Substanzen wie die Taxane und Gemcitabine intensiv auf ihre Wirksamkeit auch beim nicht metastasierten Pankreaskarzinom untersucht [2,26,29]. Beide Substanzen scheinen Radiosensitizer zu sein, hier liegen Daten aus In-vitro-Versuchen vor [16,29].…”

Section: Neuere Chemotherapeutische Substanzenunclassified

“…Aus theoretischer Sicht kann eine neoadjuvante Radiochemotherapie Vorteile gegenüber einem postoperativen adjuvanten Konzept bieten [11,16,21]. Inzwischen liegen Daten von größeren Kollektiven mit alleiniger palliativer Radiochemotherapie bei lokoregionär begrenztem Pankreaskarzinom vor [24,26]. Dosisfindungsstudien sowohl für 5-FU als auch für Gemcitabine oder die Taxane sind abgeschlossen oder werden durchgeführt [2,5,19,27,37].…”

unclassified

See 3 more Smart Citations

Strahlentherapeutische Strategien in der multimodalen Therapie des resektablen und nicht resektablen Pankreaskarzinoms

Wiegel

Runkel

Frommhold³

et al. 2000

Strahlentherapie und Onkologie

View full text Add to dashboard Cite

Due to the worse prognosis of patients with adenocarcinoma of the pancreas, new combined treatment modalities as adjuvant and neoadjuvant radio-chemotherapy, particularly with more modern chemotherapeutic agents, for patients with resectable and unresectable tumors are under investigation. For some reasons, the neoadjuvant setting seems to be better. However, these results are not proven by prospective randomized clinical trials. Therefore, these trials are necessary to define the treatment of choice in these patients. IORT is a helpful tool to improve local control. However, these aggressive multimodality approaches are only indicated in a minority of patients. In patients with unresectable tumors and good condition, combined radio-chemotherapy remains the treatment of choice.

show abstract

“…Die Lokalrezidivrate mit der alleinigen Strahlentherapie, auch mit Dosen über 50 Gy, beträgt bis zu 70% [4,26]. Das Ziel der Therapie ist sowohl eine Überlebensverlängerung [26].…”

Section: Therapiekonzepte Bei Lokoregionär Begrenztem Inoperablen Panunclassified

Section: Neuere Chemotherapeutische Substanzenunclassified

unclassified

See 2 more Smart Citations

Strahlentherapeutische Strategien in der multimodalen Therapie des resektablen und nicht resektablen Pankreaskarzinoms

Wiegel

Runkel

Frommhold³

et al. 2000

Strahlentherapie und Onkologie

View full text Add to dashboard Cite

show abstract

“…Paclitaxel A weekly paclitaxel and concurrent radiation therapy trial was completed recently for the treat- Two phase II studies were initiated to evaluate paclitaxel 50 mg/m 2 /wk with concurrent radiation therapy (at a total dose of 50 Gy) in patients with locally advanced pancreatic and gastric cancers [116,115]. After the enrollment of 25 patients in the pancreatic cancer trial, 6 of 18 evaluable patients achieved a partial response, for a preliminary response rate of 33%.…”

Section: Pancreatic and Gastric Cancersmentioning

confidence: 99%

Combining taxanes with radiation for solid tumors

Choy¹

2000

Int. J. Cancer

View full text Add to dashboard Cite

Preoperative Chemotherapy, Radiotherapy, and Surgical Resection of Locally Advanced Pancreatic Cancer

Wanebo

Glicksman²,

Vezeridis³

et al. 2000

Arch Surg

130

View full text Add to dashboard Cite

Hypothesis: Neoadjuvant therapy has the potential to induce regression of high-risk, locally advanced cancers and render them resectable. Preoperative chemoradiotherapy is proposed as a testable treatment concept for locally advanced pancreatic cancer. Design: Fourteen patients (8 men, 6 women) with locally advanced pancreatic cancer were surgically explored to exclude distant spread of disease, to perform bypass of biliary and/or gastric obstruction, and to provide a jejunostomy feeding tube for long-term nutritional support. A course of chemotherapy with fluorouracil and cisplatin plus radiotherapy was then initiated. Reexploration and resection were planned subsequent to neoadjuvant therapy. Main Outcome Measures: Tumor regression and survival. Interventions: Surgically staged patients with locally advanced pancreatic cancer were treated by preoperative chemotherapy with bolus fluorouracil, 400 mg/m 2 , on days 1 through 3 and 28 through 30 accompanied by a 3-day infusion of cisplatin, 25 mg m 2 , on days 1 through 3 and 28 through 30 and concurrent radiotherapy, 45 Gy. Enteral nutritional support was maintained via jejunostomy tube. Results: Of 14 patients who enrolled in the protocol and were initially surgically explored, 3 refused the second operation and 11 were reexplored; 2 showed progressive disease and were unresectable and 9 (81%) had definitive resection. Surgical pathologic stages of the resected patients were: Ib (2 patients), II (2 patients), and III (5 patients). Pancreatic resection included standard

show abstract

Paclitaxel and concurrent radiation for locally advanced pancreatic and gastric cancer: a phase I study.

Abstract: Concurrent paclitaxel with upper abdominal RT is well tolerated at dosages that have substantial activity. A phase II trial of neoadjuvant paclitaxel and RT at the MTD of 50 mg/m2/wk is underway.

Cited by 79 publications

References 20 publications

Strahlentherapeutische Strategien in der multimodalen Therapie des resektablen und nicht resektablen Pankreaskarzinoms

Strahlentherapeutische Strategien in der multimodalen Therapie des resektablen und nicht resektablen Pankreaskarzinoms

Combining taxanes with radiation for solid tumors

Preoperative Chemotherapy, Radiotherapy, and Surgical Resection of Locally Advanced Pancreatic Cancer

Contact Info

Product

Resources

About